Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 12, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), in line with the (12c) consensus estimate. CEO Faraz Ali said the company is entering the year with “momentum” following clinical progress in 2025, highlighting encouraging data from its lead gene therapy programs. Ali noted that Tenaya expects to provide additional updates in the first half of 2026, including longer-term data from the MyPEAK-1 trial of TN-201 and new data from the RIDGE-1 trial of TN-401, while also working toward regulatory alignment on pivotal trial plans.

On March 9, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) presented preclinical data for TN-301, its selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s Clinical & Scientific Conference 2026. In models of Duchenne muscular dystrophy, TN-301 improved muscle performance and addressed markers of muscle injury, including reductions in creatine kinase activity. The compound also showed improvements in cardiac-related cellular function, including correcting calcium handling abnormalities and mitochondrial dysfunction in human-derived cardiomyocytes.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) develops gene and small molecule therapies targeting heart disease, with programs focused on cardiomyopathies and heart failure.

While we acknowledge the risk and potential of TNYA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TNYA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.